Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 2 de 2 
Presentar resultados
Seleccionar todas
1.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P, for the SWITCHMRK1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407. [Ref.ID 87807]
2.Tiene citas relacionadas Cita con resumen
Lennox JL, DeJesus E, Lazzarín A, Pollard RB, Madruga J, Berger DS, Zhao J, Xu X, Williams-Díaz A, Rodgers AJ, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. [Ref.ID 86738]
Seleccionar todas
 
 1 a 2 de 2